section,entity_id,entity_name,entity_name_en,entity_type,category,attribute_path,value,evidence_source,source_file
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,alternate_names,原发性骨质疏松症; 继发性骨质疏松症; Osteoporosis; Primary osteoporosis; Secondary osteoporosis,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,icd10,M80.9,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,definition,以骨量低、骨微结构破坏、骨脆性增加、易发生骨折为特征的全身性代谢性骨病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_remodeling_imbalance.normal_remodeling.bone_formation,成骨细胞合成骨基质,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_remodeling_imbalance.normal_remodeling.bone_resorption,破骨细胞破坏老化骨组织,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_remodeling_imbalance.normal_remodeling.balance,健康状态下形成与吸收平衡,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_remodeling_imbalance.osteoporosis_mechanism.increased_resorption,破骨细胞活性增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_remodeling_imbalance.osteoporosis_mechanism.decreased_formation,成骨细胞功能下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_remodeling_imbalance.osteoporosis_mechanism.net_bone_loss,骨形成<骨吸收，净骨丢失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.estrogen.mechanism,抑制破骨细胞活性，促进成骨细胞功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.estrogen.deficiency_effects,绝经后雌激素缺乏导致骨吸收增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.estrogen.rankl_opg_system,调节RANKL/OPG比值影响骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.parathyroid_hormone.physiologic_role,维持血钙稳态,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.parathyroid_hormone.bone_effects,间歇性PTH促进骨形成，持续升高促进骨吸收,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.parathyroid_hormone.secondary_hyperparathyroidism,维生素D缺乏或肾功能不全引起,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.vitamin_d.calcium_absorption,促进肠道钙吸收,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.vitamin_d.bone_mineralization,必需的骨矿化因子,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.vitamin_d.deficiency_consequences,继发性甲状旁腺功能亢进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.thyroid_hormones.bone_turnover,甲亢加速骨转换,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.thyroid_hormones.fracture_risk,长期甲亢增加骨折风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.glucocorticoids.bone_formation,抑制成骨细胞分化和功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.glucocorticoids.bone_resorption,促进破骨细胞活性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.glucocorticoids.iatrogenic_osteoporosis,糖皮质激素性骨质疏松,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.growth_hormone_igf1.bone_anabolism,刺激成骨细胞增殖和胶原合成,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.hormonal_regulation.growth_hormone_igf1.deficiency,GH/IGF-1缺乏导致骨密度下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.cytokine_regulation.rank_rankl_opg.rankl,破骨细胞分化因子,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.cytokine_regulation.rank_rankl_opg.opg,骨保护素，RANKL拮抗剂,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.cytokine_regulation.rank_rankl_opg.ratio,RANKL/OPG比值决定骨吸收程度,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.cytokine_regulation.inflammatory_cytokines.il1_il6_tnf,促进骨吸收的细胞因子,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,pathophysiology.cytokine_regulation.inflammatory_cytokines.chronic_inflammation,慢性炎症加速骨丢失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.primary_osteoporosis.type_1.description,绝经后骨质疏松,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.primary_osteoporosis.type_1.age_group,51-75岁女性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.primary_osteoporosis.type_1.mechanism,雌激素缺乏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.primary_osteoporosis.type_1.predominant_site,松质骨（椎体、桡骨远端）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.primary_osteoporosis.type_2.description,老年性骨质疏松,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.primary_osteoporosis.type_2.age_group,>70岁男女,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.primary_osteoporosis.type_2.mechanism,年龄相关的骨形成减少,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.primary_osteoporosis.type_2.predominant_site,皮质骨和松质骨,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.secondary_osteoporosis.endocrine_causes,甲状腺功能亢进; 甲状旁腺功能亢进; Cushing综合征; 性腺功能减退; 糖尿病; 甲状旁腺功能减退,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.secondary_osteoporosis.drug_induced,糖皮质激素; 抗癫痫药; 肝素; 芳香化酶抑制剂; GnRH激动剂,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.etiology_based.secondary_osteoporosis.systemic_diseases,类风湿关节炎; 慢性肾病; 炎症性肠病; 慢性阻塞性肺病; 肝病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.severity_based.osteopenia.t_score,-1.0到-2.5之间,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.severity_based.osteopenia.description,骨量减少,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.severity_based.osteoporosis.t_score,≤-2.5,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.severity_based.osteoporosis.description,骨质疏松症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.severity_based.severe_osteoporosis.criteria,骨质疏松症+脆性骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,classification.severity_based.severe_osteoporosis.description,严重骨质疏松症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,epidemiology.prevalence.global,全球>2亿人患病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,epidemiology.prevalence.china.overall,中国50岁以上人群患病率约13%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,epidemiology.prevalence.china.women,绝经后女性患病率30-50%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,epidemiology.prevalence.china.men,男性患病率相对较低，约为女性1/4,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,epidemiology.fracture_epidemiology.lifetime_risk,50岁后终生骨折风险：女性40%，男性20%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,epidemiology.fracture_epidemiology.common_sites,髋部（死亡率最高）; 脊椎（最常见）; 桡骨远端; 肱骨近端,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,epidemiology.fracture_epidemiology.mortality,髋部骨折1年死亡率15-25%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,epidemiology.economic_burden.medical_costs,年医疗费用数千亿,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,epidemiology.economic_burden.indirect_costs,护理、失能等间接成本巨大,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.non_modifiable.age,最重要的危险因素,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.non_modifiable.gender,女性>男性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.non_modifiable.race,白种人和亚洲人风险较高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.non_modifiable.genetics,COL1A1基因多态性; 维生素D受体基因变异; 雌激素受体基因多态性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.non_modifiable.family_history,骨折家族史增加风险2倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.non_modifiable.previous_fracture,既往脆性骨折是最强预测因子,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.potentially_modifiable.hormonal_factors,早绝经（<45岁）; 晚初潮（>15岁）; 性腺功能减退; 不孕或少孕,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.potentially_modifiable.lifestyle_factors,低钙摄入（<800mg/天）; 维生素D缺乏; 吸烟; 过量饮酒（>2单位/天）; 缺乏运动; 低体重（BMI<19）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.potentially_modifiable.medical_conditions,类风湿关节炎; 炎症性肠病; 慢性肾病; 慢性阻塞性肺病; 恶性肿瘤,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.potentially_modifiable.medications,糖皮质激素（>3个月）; 抗癫痫药; 质子泵抑制剂; 噻嗪类利尿剂; 抗凝剂,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.asymptomatic_phase.description,早期通常无明显症状,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.asymptomatic_phase.silent_progression,骨密度逐渐降低但无临床表现,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.asymptomatic_phase.importance,需要主动筛查才能发现,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.symptomatic_phase.bone_pain.characteristics,慢性、钝痛，活动后加重,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.symptomatic_phase.bone_pain.location,腰背部最常见,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.symptomatic_phase.bone_pain.mechanism,微骨折或骨小梁断裂,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.symptomatic_phase.height_loss.mechanism,胸腰椎压缩性骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.symptomatic_phase.height_loss.progression,身高逐渐降低，>4cm提示椎体骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.symptomatic_phase.kyphosis.description,胸椎后凸畸形（驼背）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.symptomatic_phase.kyphosis.consequence,多个椎体压缩性骨折累积效应,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.symptomatic_phase.functional_impairment.mobility,活动能力下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.symptomatic_phase.functional_impairment.balance,平衡功能受损,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.symptomatic_phase.functional_impairment.falls_risk,跌倒风险增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.fragility_fractures.definition,轻微外伤或无外伤情况下发生的骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.fragility_fractures.vertebral_fractures.prevalence,最常见的骨质疏松性骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.fragility_fractures.vertebral_fractures.clinical_presentation,急性腰背痛; 身高降低; 后凸畸形; 呼吸功能受限,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.fragility_fractures.vertebral_fractures.complications,疼痛、畸形、肺功能下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.fragility_fractures.hip_fractures.types,股骨颈骨折、转子间骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.fragility_fractures.hip_fractures.consequences,致残率和死亡率最高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.fragility_fractures.hip_fractures.recovery,需要手术，恢复时间长,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.fragility_fractures.distal_radius_fractures.mechanism,跌倒时手掌撑地,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.fragility_fractures.distal_radius_fractures.typical_patients,绝经后早期女性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.clinical_assessment.history_taking,骨折史和家族史; 药物使用史; 生活方式评估; 内分泌疾病史; 消化系统疾病史,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.clinical_assessment.physical_examination,身高和体重测量; 脊柱检查（后凸、压痛）; 肌力和平衡评估; 跌倒风险评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_density_measurement.dexa_scan.gold_standard,双能X线骨密度测定,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_density_measurement.dexa_scan.measurement_sites,腰椎、髋部、前臂,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_density_measurement.dexa_scan.t_score,与同性别峰值骨密度比较,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_density_measurement.dexa_scan.z_score,与同年龄同性别比较,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_density_measurement.quantitative_ct.advantages,真正的体积骨密度,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_density_measurement.quantitative_ct.applications,椎体骨密度测量,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_density_measurement.quantitative_ct.limitations,辐射剂量高，费用昂贵,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_density_measurement.ultrasound.sites,跟骨、胫骨,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_density_measurement.ultrasound.parameters,声速（SOS）、宽带超声衰减（BUA）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_density_measurement.ultrasound.applications,筛查工具，不能诊断,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.bone_formation_markers,骨特异性碱性磷酸酶（BALP）; 骨钙蛋白（OC）; I型前胶原氨基端肽（PINP）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.bone_resorption_markers,I型胶原羧基端肽（CTX）; 尿N-端中分子片段（NTX）; 尿吡啶啉、脱氧吡啶啉,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.clinical_applications,治疗监测; 骨转换评估; 预后判断,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.secondary_causes_evaluation.laboratory_tests,血钙、磷、镁; 25-羟维生素D; 甲状旁腺激素（PTH）; 甲状腺功能; 性激素水平; 24小时尿钙; 肾功能; 肝功能; 炎症指标,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.secondary_causes_evaluation.additional_tests,血清蛋白电泳（排除多发性骨髓瘤）; 尿本-琼蛋白; 皮质醇（疑似Cushing综合征）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_evaluation.spine_xray.purpose,检测椎体骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_evaluation.spine_xray.findings,椎体高度丢失、楔形变、双凹征,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_evaluation.vertebral_fracture_assessment.vfa,椎体骨折评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_evaluation.vertebral_fracture_assessment.method,DXA侧位脊柱成像,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_evaluation.vertebral_fracture_assessment.advantages,低辐射、快速,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.nutrition.calcium,1000-1200mg/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.nutrition.vitamin_d,800-1000IU/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.nutrition.protein,1.0-1.2g/kg体重/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.nutrition.dietary_sources,乳制品、绿叶蔬菜、鱼类,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.exercise.weight_bearing,步行、慢跑、爬楼梯,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.exercise.resistance_training,肌肉力量训练,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.exercise.balance_training,太极、瑜伽防跌倒,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.exercise.frequency,每周3-4次，每次30-45分钟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.fall_prevention.home_safety,移除障碍物、增加照明,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.fall_prevention.vision_correction,定期眼科检查,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.fall_prevention.medication_review,避免增加跌倒风险的药物,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.fall_prevention.assistive_devices,手杖、助行器的使用,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.lifestyle_changes.smoking_cessation,戒烟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.lifestyle_changes.alcohol_moderation,限制酒精摄入,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.non_pharmacological.lifestyle_modifications.lifestyle_changes.maintain_healthy_weight,避免低体重,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.bisphosphonates.mechanism,抑制破骨细胞活性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.bisphosphonates.agents,阿仑膦酸钠（每周70mg）; 利塞膦酸钠（每周35mg）; 伊班膦酸钠（每月150mg）; 唑来膦酸（每年5mg静脉）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.bisphosphonates.efficacy,降低椎体骨折50-70%，髋部骨折40-50%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.bisphosphonates.side_effects,上消化道刺激; 急性期反应（发热、肌痛）; 颌骨坏死（罕见）; 非典型股骨骨折（长期使用）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.bisphosphonates.contraindications,食道狭窄; 严重肾功能不全（GFR<30ml/min）; 低钙血症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.denosumab.mechanism,RANKL单克隆抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.denosumab.dosage,60mg皮下注射，每6个月1次,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.denosumab.efficacy,椎体骨折68%，髋部骨折40%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.denosumab.advantages,不依赖肾功能清除,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.denosumab.side_effects,感染风险增加; 低钙血症; 皮肤反应; 颌骨坏死,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.denosumab.rebound_effect,停药后骨丢失快速反弹,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.selective_estrogen_receptor_modulators.raloxifene.mechanism,选择性雌激素受体调节剂,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.selective_estrogen_receptor_modulators.raloxifene.dosage,60mg/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.selective_estrogen_receptor_modulators.raloxifene.efficacy,椎体骨折30-50%，无髋部骨折获益,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.selective_estrogen_receptor_modulators.raloxifene.additional_benefits,降低浸润性乳腺癌风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.antiresorptive_agents.selective_estrogen_receptor_modulators.raloxifene.side_effects,静脉血栓栓塞风险增加; 潮热; 腿部痉挛,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.parathyroid_hormone_analogs.teriparatide.mechanism,重组人甲状旁腺激素1-34,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.parathyroid_hormone_analogs.teriparatide.dosage,20μg/天皮下注射,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.parathyroid_hormone_analogs.teriparatide.duration,最长24个月,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.parathyroid_hormone_analogs.teriparatide.efficacy,椎体骨折65%，非椎体骨折53%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.parathyroid_hormone_analogs.teriparatide.indications,严重骨质疏松，多发骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.parathyroid_hormone_analogs.teriparatide.contraindications,恶性肿瘤病史; 骨肉瘤风险; 严重肾功能不全,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.parathyroid_hormone_analogs.abaloparatide.mechanism,PTHrP类似物,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.parathyroid_hormone_analogs.abaloparatide.advantages,较特立帕肽副作用更少,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.sclerostin_inhibitor.romosozumab.mechanism,sclerostin单克隆抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.sclerostin_inhibitor.romosozumab.dosage,210mg皮下注射，每月1次,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.sclerostin_inhibitor.romosozumab.duration,12个月,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.sclerostin_inhibitor.romosozumab.efficacy,椎体骨折73%，髋部骨折38%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.anabolic_agents.sclerostin_inhibitor.romosozumab.cardiovascular_risk,心血管事件风险可能增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.hormone_replacement.estrogen_therapy.indications,绝经后早期症状明显的女性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.hormone_replacement.estrogen_therapy.benefits,骨密度增加，骨折风险降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.hormone_replacement.estrogen_therapy.risks,乳腺癌风险增加; 静脉血栓栓塞; 卒中风险; 冠心病风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.hormone_replacement.estrogen_therapy.considerations,风险效益权衡，个体化治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.hormone_replacement.testosterone_replacement.indications,男性性腺功能减退伴骨质疏松,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.pharmacological.hormone_replacement.testosterone_replacement.monitoring,前列腺安全性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.combination_therapy.sequential_therapy.anabolic_first,先使用促骨形成药物,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.combination_therapy.sequential_therapy.followed_by_antiresorptive,后续抗骨吸收治疗维持,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.combination_therapy.monitoring.bone_density,每1-2年复查DXA,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.combination_therapy.monitoring.biochemical_markers,治疗3-6个月后评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,treatment.combination_therapy.monitoring.safety_monitoring,定期评估药物不良反应,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,complications.fracture_complications.vertebral_fractures,慢性疼痛; 脊柱后凸畸形; 身高丢失; 肺功能受限; 胃肠功能异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,complications.fracture_complications.hip_fractures,长期卧床并发症; 深静脉血栓; 肺栓塞; 泌尿系感染; 压疮; 肌肉萎缩,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,complications.fracture_complications.cascade_fractures,一次骨折后后续骨折风险显著增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,complications.quality_of_life.physical_function,活动能力下降，自理能力受损,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,complications.quality_of_life.psychological_impact,抑郁、焦虑、社会退缩,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,complications.quality_of_life.social_consequences,家庭和社会负担增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,complications.mortality.hip_fracture_mortality,髋部骨折后1年死亡率15-25%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,complications.mortality.vertebral_fracture_mortality,椎体骨折死亡率增加23%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,complications.mortality.excess_mortality,骨质疏松相关超额死亡,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prevention.primary_prevention.target_population,尚未发生骨质疏松的人群,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prevention.primary_prevention.strategies,优化峰值骨量（青少年期）; 维持骨量（成年期）; 减缓骨丢失（绝经期）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prevention.primary_prevention.interventions,充足钙和维生素D摄入; 规律体力活动; 健康生活方式; 避免危险因素,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prevention.secondary_prevention.target_population,已有骨质疏松但未发生骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prevention.secondary_prevention.goal,预防首次骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prevention.secondary_prevention.interventions,药物治疗+非药物治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prevention.tertiary_prevention.target_population,已发生脆性骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prevention.tertiary_prevention.goal,防止后续骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prevention.tertiary_prevention.fracture_liaison_service,骨折联络服务模式,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prognosis.factors_affecting_prognosis,年龄; 基线骨密度; 骨折史; 伴发疾病; 治疗依从性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prognosis.treatment_response.bone_density_improvement,治疗1-2年骨密度增加3-8%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prognosis.treatment_response.fracture_risk_reduction,抗骨吸收药物降低骨折风险30-70%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prognosis.treatment_response.time_to_benefit,椎体骨折6-12个月，髋部骨折2-3年,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prognosis.long_term_outcomes.continued_treatment,长期治疗可持续获益,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prognosis.long_term_outcomes.drug_holidays,某些患者可考虑停药假期,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,prognosis.long_term_outcomes.lifelong_monitoring,需要终身监测和管理,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_001.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,alternate_names,软骨病; 维生素D缺乏性骨病; Osteomalacia; Rickets (in children); Adult rickets,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,icd10,M83.9,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,definition,由于骨基质矿化缺陷导致的骨病，特征是骨基质正常但矿物质沉积不足,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.mineralization_defect.normal_bone_formation,成骨细胞正常合成骨基质（类骨质）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.mineralization_defect.impaired_mineralization,钙磷酸盐晶体沉积障碍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.mineralization_defect.accumulation_of_osteoid,未矿化的类骨质异常增多,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.synthesis_pathway.step1,皮肤7-脱氢胆固醇→维生素D3（阳光照射）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.synthesis_pathway.step2,肝脏25-羟化酶→25(OH)D3（储存形式）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.synthesis_pathway.step3,"肾脏1α-羟化酶→1,25(OH)2D3（活性形式）",ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.physiological_functions.intestinal_calcium_absorption,促进小肠钙吸收（主要功能）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.physiological_functions.phosphate_absorption,促进磷酸盐吸收,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.physiological_functions.bone_mineralization,直接促进骨矿化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.physiological_functions.pth_regulation,抑制甲状旁腺激素分泌,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.physiological_functions.fgf23_interaction,与FGF23相互调节磷代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.deficiency_consequences.decreased_calcium_absorption,肠道钙吸收减少,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.deficiency_consequences.secondary_hyperparathyroidism,继发性甲状旁腺功能亢进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.deficiency_consequences.phosphate_wasting,肾脏磷酸盐丢失增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.vitamin_d_metabolism.deficiency_consequences.mineralization_failure,骨和牙齿矿化障碍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.calcium_phosphate_homeostasis.normal_mineral_balance.serum_calcium,2.20-2.60mmol/L,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.calcium_phosphate_homeostasis.normal_mineral_balance.serum_phosphate,0.85-1.45mmol/L,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.calcium_phosphate_homeostasis.normal_mineral_balance.calcium_phosphate_product,正常时>40,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.calcium_phosphate_homeostasis.disturbed_homeostasis.low_serum_calcium,维生素D缺乏导致低钙血症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.calcium_phosphate_homeostasis.disturbed_homeostasis.low_serum_phosphate,继发性甲状旁腺功能亢进导致磷酸盐流失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.calcium_phosphate_homeostasis.disturbed_homeostasis.inadequate_mineral_product,钙磷乘积不足以支持矿化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_matrix_abnormalities.osteoid_accumulation.mechanism,类骨质合成正常但矿化延迟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_matrix_abnormalities.osteoid_accumulation.histological_features,类骨质厚度增加，矿化滞后时间延长,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_matrix_abnormalities.osteoid_accumulation.osteoid_volume,正常<5%，骨软化症>12%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_matrix_abnormalities.pseudofractures.looser_zones,Looser假性骨折线,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_matrix_abnormalities.pseudofractures.locations,肋骨、骨盆、股骨内侧皮质,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_matrix_abnormalities.pseudofractures.mechanism,重复微损伤和修复不良,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_deficiency.inadequate_sunlight_exposure,室内工作人群; 高纬度地区居民; 宗教文化因素（全身覆盖）; 空气污染严重地区,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_deficiency.dietary_insufficiency,素食主义者; 乳糖不耐受; 饮食结构单一; 食物维生素D含量低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_deficiency.malabsorption,脂肪泻; 炎症性肠病; 胃切除术后; 胰腺功能不全; 胆汁酸合成障碍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_metabolism_disorders.1alpha_hydroxylase_deficiency.genetic_defect,CYP27B1基因突变,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_metabolism_disorders.1alpha_hydroxylase_deficiency.clinical_name,维生素D依赖性佝偻病I型,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_metabolism_disorders.1alpha_hydroxylase_deficiency.biochemical_profile,"25(OH)D正常，1,25(OH)2D低",ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_metabolism_disorders.vitamin_d_receptor_defects.genetic_defect,VDR基因突变,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_metabolism_disorders.vitamin_d_receptor_defects.clinical_name,维生素D依赖性佝偻病II型,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_metabolism_disorders.vitamin_d_receptor_defects.biochemical_profile,"1,25(OH)2D高，组织抵抗",ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_metabolism_disorders.24_hydroxylase_mutations.genetic_defect,CYP24A1基因突变,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.vitamin_d_metabolism_disorders.24_hydroxylase_mutations.consequence,维生素D分解减少，中毒易感性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.phosphate_depletion.hereditary_hypophosphatemic_rickets.x_linked,PHEX基因突变（最常见）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.phosphate_depletion.hereditary_hypophosphatemic_rickets.autosomal_dominant,FGF23基因突变,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.phosphate_depletion.hereditary_hypophosphatemic_rickets.autosomal_recessive,DMP1或ENPP1基因突变,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.phosphate_depletion.hereditary_hypophosphatemic_rickets.mechanism,FGF23过度表达导致肾脏磷酸盐丢失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.phosphate_depletion.tumor_induced_osteomalacia.mechanism,肿瘤分泌FGF23类似物质,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.phosphate_depletion.tumor_induced_osteomalacia.tumor_types,间叶性肿瘤、前列腺癌、肺癌,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.phosphate_depletion.tumor_induced_osteomalacia.clinical_course,肿瘤切除后快速恢复,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.phosphate_depletion.drug_induced,磷酸结合剂过量; 抗癫痫药物; 铁剂螯合剂; 双膦酸盐（大剂量）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.renal_tubular_disorders.fanconi_syndrome,近端肾小管功能全面异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.renal_tubular_disorders.distal_renal_tubular_acidosis,远端肾小管酸化功能缺陷,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.renal_tubular_disorders.chronic_kidney_disease,肾脏1α-羟化酶活性下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.matrix_disorders.hypophosphatasia.enzyme_defect,组织非特异性碱性磷酸酶缺陷,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.matrix_disorders.hypophosphatasia.clinical_spectrum,从致命性到轻微骨病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.matrix_disorders.hypophosphatasia.biochemical_marker,血清碱性磷酸酶低，尿磷酸乙醇胺高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,etiology.matrix_disorders.fibrogenesis_imperfecta_ossium,罕见的骨基质异常疾病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.bone_pain.characteristics,弥漫性、深部钝痛,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.bone_pain.distribution,腰背部、髋部、胸部最常见,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.bone_pain.aggravating_factors,活动、负重,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.bone_pain.pattern,对称性分布,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.muscle_weakness.pattern,近端肌群受累为主,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.muscle_weakness.manifestations,上楼困难; 从坐位站起困难; 举臂无力; 步态摇摆,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.muscle_weakness.mechanism,维生素D缺乏直接影响肌肉功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.skeletal_deformities.spinal_deformity,脊柱侧弯、后凸,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.skeletal_deformities.chest_deformity,漏斗胸、鸡胸,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.skeletal_deformities.limb_deformity,下肢弯曲变形,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.skeletal_deformities.pelvic_deformity,骨盆狭窄（影响分娩）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.fractures.types,病理性骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.fractures.common_sites,脊椎、髋部、前臂,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.adult_presentation.fractures.healing,骨折愈合延迟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.growth_retardation,身高和体重增长迟缓,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.dental_problems,牙齿萌出延迟; 牙釉质缺陷; 龋齿多发; 牙齿松动,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.cranial_changes.craniotabes,颅骨软化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.cranial_changes.delayed_fontanelle_closure,囟门闭合延迟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.cranial_changes.frontal_bossing,前额突出,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.thoracic_deformity.rachitic_rosary,佝偻病串珠（肋软骨交界处膨大）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.thoracic_deformity.harrison_groove,横行胸沟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.thoracic_deformity.pectus_deformity,鸡胸或漏斗胸,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.limb_deformities.genu_valgum,膝外翻（X型腿）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.limb_deformities.genu_varum,膝内翻（O型腿）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.limb_deformities.coxa_vara,髋内翻,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.pediatric_presentation.limb_deformities.delayed_walking,行走延迟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.systemic_manifestations.hypocalcemic_symptoms,手足搐搦症; 肌肉痉挛; 感觉异常; 癫痫发作,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.systemic_manifestations.secondary_hyperparathyroidism,骨痛加重; 尿路结石; 肾功能损害; 高血压,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,clinical_manifestations.systemic_manifestations.immune_dysfunction,感染易感性增加; 自身免疫疾病风险; 疫苗应答减弱,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.clinical_assessment.history,膳食习惯评估; 阳光照射史; 药物使用史; 消化系统疾病史; 肾脏疾病史; 家族史,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.clinical_assessment.physical_examination,骨骼系统检查; 肌力评估; 神经系统检查; Chvostek征和Trousseau征,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.vitamin_d_status.25_oh_d.test,血清25-羟维生素D,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.vitamin_d_status.25_oh_d.deficiency,<20ng/mL (50nmol/L),ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.vitamin_d_status.25_oh_d.insufficiency,20-30ng/mL (50-75nmol/L),ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.vitamin_d_status.25_oh_d.sufficiency,>30ng/mL (75nmol/L),ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.vitamin_d_status.1_25_oh2_d.test,"血清1,25-二羟维生素D",ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.vitamin_d_status.1_25_oh2_d.normal_range,20-60pg/mL,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.vitamin_d_status.1_25_oh2_d.clinical_utility,评估肾脏1α-羟化酶功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.mineral_metabolism.serum_calcium.typical_finding,正常或轻度降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.mineral_metabolism.serum_calcium.severe_deficiency,明显低钙血症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.mineral_metabolism.serum_phosphate.pattern,通常降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.mineral_metabolism.serum_phosphate.mechanism,继发性甲状旁腺功能亢进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.mineral_metabolism.parathyroid_hormone.finding,显著升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.mineral_metabolism.parathyroid_hormone.range,正常值的2-10倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.mineral_metabolism.alkaline_phosphatase.pattern,升高（骨型ALP）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.mineral_metabolism.alkaline_phosphatase.significance,反映骨转换增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.bone_turnover_markers.formation_markers,骨特异性碱性磷酸酶升高; 骨钙蛋白升高; PINP升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.bone_turnover_markers.resorption_markers,CTX升高; NTX升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.urinary_markers.24h_urine_calcium,通常降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.urinary_markers.24h_urine_phosphate,继发性甲状旁腺功能亢进时增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_markers.urinary_markers.tubular_reabsorption_phosphate,降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.conventional_radiography.characteristic_findings,骨密度普遍降低; 皮质骨变薄; 小梁骨稀疏; Looser假性骨折线,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.conventional_radiography.looser_zones.definition,对称性透明带，垂直于骨皮质,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.conventional_radiography.looser_zones.common_sites,股骨内侧颈部; 耻骨支; 肋骨; 肩胛骨内缘,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.conventional_radiography.looser_zones.pathognomonic,骨软化症的特征性表现,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.conventional_radiography.pediatric_findings,骨骺钙化延迟; 干骺端杯状变形; 骨干弯曲变形; 颅骨软化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_densitometry.dexa_findings,骨密度显著降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_densitometry.pattern,全身性骨密度减少,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_densitometry.monitoring,治疗效果评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.advanced_imaging.bone_scintigraphy.pattern,多发性骨痛区域摄取增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.advanced_imaging.bone_scintigraphy.pseudofracture_sites,Looser带区域异常摄取,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.advanced_imaging.mri_findings,骨髓水肿; 应力性改变; 肌肉信号异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_biopsy.indications,诊断不明确时; 疑似其他骨病; 治疗反应差; 研究目的,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_biopsy.histological_features.increased_osteoid,类骨质体积>12%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_biopsy.histological_features.delayed_mineralization,矿化滞后时间>100天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_biopsy.histological_features.osteoid_thickness,类骨质厚度增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_biopsy.histological_features.mineralization_front,矿化前沿稀少,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.bone_biopsy.technique,经皮髂骨活检（双标记技术）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.differential_diagnosis.osteoporosis.distinguishing_features,骨软化症有假性骨折线和肌肉症状,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.differential_diagnosis.osteoporosis.biochemical_differences,骨软化症PTH明显升高，25(OH)D缺乏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.differential_diagnosis.hyperparathyroidism.primary_hpt,骨软化症PTH升高是继发性的,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.differential_diagnosis.hyperparathyroidism.calcium_levels,原发性甲状旁腺功能亢进血钙升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.differential_diagnosis.malignancy.metastatic_bone_disease,影像学和病史可鉴别,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,diagnosis.differential_diagnosis.malignancy.multiple_myeloma,血清蛋白电泳、骨髓检查,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.vitamin_d3_cholecalciferol.standard_dose,1000-4000IU/天（维持）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.vitamin_d3_cholecalciferol.loading_dose,50000IU/周，持续8-12周（严重缺乏）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.vitamin_d3_cholecalciferol.high_dose,10000-50000IU/天（严重骨软化症）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.vitamin_d3_cholecalciferol.duration,通常需要终身补充,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.vitamin_d2_ergocalciferol.equivalency,与维生素D3基本等效,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.vitamin_d2_ergocalciferol.dosing,类似维生素D3方案,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.vitamin_d2_ergocalciferol.preference,维生素D3更优（生物利用度更好）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.active_metabolites.calcitriol.indications,严重肾功能不全; 1α-羟化酶缺陷; 急需快速纠正低钙血症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.active_metabolites.calcitriol.dosing,0.25-2.0μg/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.active_metabolites.calcitriol.monitoring,密切监测血钙避免中毒,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.active_metabolites.alfacalcidol.mechanism,1α-羟维生素D3，需肝脏25-羟化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.active_metabolites.alfacalcidol.dosing,0.5-3.0μg/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.vitamin_d_replacement.active_metabolites.alfacalcidol.advantages,较calcitriol作用温和持久,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.mineral_supplementation.calcium_supplementation.elemental_calcium,1000-1500mg/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.mineral_supplementation.calcium_supplementation.forms,碳酸钙（含钙40%）; 柠檬酸钙（含钙21%，吸收更好）; 醋酸钙（含钙25%）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.mineral_supplementation.calcium_supplementation.timing,分次服用，餐时或餐后,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.mineral_supplementation.calcium_supplementation.monitoring,避免过量导致结石,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.mineral_supplementation.phosphate_supplementation.indications,遗传性低磷血症性佝偻病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.mineral_supplementation.phosphate_supplementation.forms,磷酸钠; 磷酸钾; 中性磷酸盐,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.mineral_supplementation.phosphate_supplementation.dosing,30-60mg/kg/天（分3-4次）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.mineral_supplementation.phosphate_supplementation.side_effects,腹泻; 腹痛; 恶心; 继发性甲状旁腺功能亢进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.xlh_treatment.conventional,磷酸盐+活性维生素D,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.xlh_treatment.burosumab.mechanism,FGF23单克隆抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.xlh_treatment.burosumab.dosing,0.8-1.2mg/kg皮下注射，每2周一次,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.xlh_treatment.burosumab.efficacy,显著改善磷酸盐水平和骨病变,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.xlh_treatment.burosumab.monitoring,肾功能、甲状旁腺功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.vddr1_treatment.calcitriol,0.5-2.0μg/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.vddr1_treatment.calcium,1000-1500mg/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.vddr1_treatment.response,通常反应良好,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.vddr2_treatment.high_dose_calcitriol,5-30μg/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.vddr2_treatment.intravenous_calcium,重症患者需要静脉补钙,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.hereditary_rickets.vddr2_treatment.prognosis,部分患者对治疗抵抗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.tumor_induced_osteomalacia.tumor_localization,全身PET-CT扫描; 奥曲肽扫描; 静脉取样检测FGF23,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.tumor_induced_osteomalacia.surgical_treatment,完整肿瘤切除,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.specific_therapies.tumor_induced_osteomalacia.medical_management,手术前或不能手术时磷酸盐补充,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.supportive_care.physical_therapy.objectives,改善肌力; 增加关节活动度; 防止跌倒; 矫正姿势,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.supportive_care.physical_therapy.exercise_program,水中运动（减少关节负荷）; 等长肌力训练; 平衡训练; 柔韧性练习,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.supportive_care.orthopedic_intervention.indications,严重骨骼畸形; 病理性骨折; 关节功能障碍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.supportive_care.orthopedic_intervention.procedures,截骨矫正术; 内固定治疗; 关节置换术,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.supportive_care.orthopedic_intervention.timing,通常在生化指标纠正后进行,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.supportive_care.dietary_counseling.vitamin_d_rich_foods,富脂鱼类（鲑鱼、鲭鱼）; 强化乳制品; 蛋黄; 强化谷物,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,treatment.supportive_care.dietary_counseling.calcium_rich_foods,乳制品; 绿叶蔬菜; 坚果和种子; 豆制品,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.biochemical_monitoring.frequency,治疗前3个月每月检查，稳定后每3-6个月,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.biochemical_monitoring.parameters,血清钙; 血清磷; 甲状旁腺激素; 25-羟维生素D; 碱性磷酸酶; 24小时尿钙,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.biochemical_monitoring.target_levels.25_oh_d,>30ng/mL (75nmol/L),ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.biochemical_monitoring.target_levels.pth,恢复正常范围,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.biochemical_monitoring.target_levels.serum_calcium,正常范围,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.biochemical_monitoring.target_levels.urine_calcium,<4mg/kg/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.clinical_monitoring.symptoms,骨痛、肌力、行走能力改善,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.clinical_monitoring.imaging,每6-12个月骨密度检查，必要时X线复查,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.clinical_monitoring.complications,监测维生素D中毒、肾结石、肾功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.treatment_response.early_response,2-4周内症状开始改善,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.treatment_response.biochemical_normalization,3-6个月内PTH和ALP开始下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.treatment_response.radiological_healing,6-12个月假性骨折线愈合,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,monitoring.treatment_response.complete_recovery,1-2年骨密度显著改善,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,prognosis.factors_affecting_outcome,诊断和治疗及时性; 维生素D缺乏严重程度; 患者年龄和依从性; 潜在病因是否可纠正,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,prognosis.treatment_response.nutritional_osteomalacia,治疗反应通常很好,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,prognosis.treatment_response.genetic_forms,需要终身治疗，预后变异较大,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,prognosis.treatment_response.tumor_induced,肿瘤切除后可完全恢复,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,prognosis.complications.untreated_consequences,进行性骨骼畸形; 病理性骨折; 肌无力和功能障碍; 生长发育迟缓（儿童）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_002,BONE_002,骨软化症,,骨代谢疾病,骨代谢疾病,prognosis.complications.treatment_complications,维生素D中毒; 高钙血症; 肾结石; 肾功能损害,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_002.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,alternate_names,甲状旁腺功能亢进性骨病; 纤维囊性骨炎; 褐色瘤; Hyperparathyroid bone disease; Osteitis fibrosa cystica; Brown tumor,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,icd10,E21.0,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,definition,由甲状旁腺激素过多分泌引起的骨代谢异常，特征是骨吸收增加、纤维组织增生和囊性病变,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.parathyroid_hormone_effects.bone_remodeling.increased_osteoclast_activity,PTH直接和间接激活破骨细胞,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.parathyroid_hormone_effects.bone_remodeling.rankl_opg_system,PTH上调RANKL表达，下调OPG,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.parathyroid_hormone_effects.bone_remodeling.bone_resorption,骨吸收显著增加，超过骨形成,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.parathyroid_hormone_effects.calcium_homeostasis.bone_calcium_mobilization,从骨骼释放钙入血,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.parathyroid_hormone_effects.calcium_homeostasis.renal_calcium_reabsorption,肾小管钙重吸收增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.parathyroid_hormone_effects.calcium_homeostasis.intestinal_absorption,"通过促进1,25(OH)2D3合成间接促进肠道钙吸收",ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.parathyroid_hormone_effects.phosphate_metabolism.renal_phosphate_wasting,抑制近端肾小管磷重吸收,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.parathyroid_hormone_effects.phosphate_metabolism.hypophosphatemia,血磷降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.parathyroid_hormone_effects.phosphate_metabolism.fgf23_interaction,与FGF23相互作用调节磷代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_histological_changes.osteitis_fibrosa.mechanism,过度骨吸收后纤维组织填充,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_histological_changes.osteitis_fibrosa.microscopy,骨小梁减少，纤维组织增生，破骨细胞增多,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_histological_changes.osteitis_fibrosa.severity_grading,轻度→中度→重度纤维囊性骨炎,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_histological_changes.brown_tumors.pathogenesis,局灶性骨吸收和出血形成含铁血黄素沉积,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_histological_changes.brown_tumors.locations,颌骨、肋骨、骨盆、长骨最常见,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_histological_changes.brown_tumors.histology,巨细胞、纤维组织、含铁血黄素,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_histological_changes.subperiosteal_resorption.definition,骨膜下皮质骨吸收,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_histological_changes.subperiosteal_resorption.classic_sites,指骨桡侧、锁骨远端、骶髂关节,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.bone_histological_changes.subperiosteal_resorption.radiologic_appearance,虫蚀样改变,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.systemic_effects.hypercalcemia_consequences,神经肌肉症状; 肾脏损害; 胃肠道症状; 心血管影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.systemic_effects.bone_fragility.cortical_thinning,皮质骨变薄,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.systemic_effects.bone_fragility.trabecular_loss,小梁骨丢失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,pathophysiology.systemic_effects.bone_fragility.fracture_risk,病理性骨折风险增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.parathyroid_adenoma.prevalence,80-85%的原发性甲状旁腺功能亢进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.parathyroid_adenoma.characteristics,单个腺体良性肿瘤,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.parathyroid_adenoma.pth_secretion,自主性PTH分泌,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.parathyroid_hyperplasia.prevalence,15%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.parathyroid_hyperplasia.types,弥漫性四腺体增生; 结节性增生; 不均匀增生,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.parathyroid_hyperplasia.genetic_associations,MEN1综合征; MEN2A综合征; 家族性低钙尿性高钙血症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.parathyroid_carcinoma.prevalence,<1%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.parathyroid_carcinoma.characteristics,恶性肿瘤，PTH极度升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.parathyroid_carcinoma.clinical_features,严重高钙血症，骨病变显著,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.multiple_adenomas.prevalence,2-5%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.primary_hyperparathyroidism.multiple_adenomas.challenge,术中识别所有病变腺体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.secondary_hyperparathyroidism.chronic_kidney_disease.mechanism,1α-羟化酶活性下降; 磷潴留; 钙吸收减少; 代谢性酸中毒,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.secondary_hyperparathyroidism.chronic_kidney_disease.stages,CKD 3期开始出现PTH升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.secondary_hyperparathyroidism.chronic_kidney_disease.bone_disease,肾性骨病（ROD）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.secondary_hyperparathyroidism.vitamin_d_deficiency.mechanism,肠道钙吸收减少触发PTH分泌,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.secondary_hyperparathyroidism.vitamin_d_deficiency.bone_effects,与骨软化症并存,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.secondary_hyperparathyroidism.vitamin_d_deficiency.reversibility,维生素D补充可逆转,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.secondary_hyperparathyroidism.malabsorption_syndromes,炎症性肠病; 胃肠道手术后; 胰腺功能不全; 乳糜泻,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.secondary_hyperparathyroidism.medications,双膦酸盐过量; 去氟骨化醇; 磷酸结合剂过量,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.tertiary_hyperparathyroidism.definition,继发性甲状旁腺功能亢进基础上腺体自主化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.tertiary_hyperparathyroidism.common_setting,慢性肾病透析患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.tertiary_hyperparathyroidism.characteristics,PTH分泌不受血钙调节,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,etiology.tertiary_hyperparathyroidism.treatment,通常需要外科干预,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.bone_symptoms.bone_pain.characteristics,弥漫性骨痛，活动时加重,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.bone_symptoms.bone_pain.distribution,脊柱、骨盆、四肢长骨,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.bone_symptoms.bone_pain.severity,与PTH水平和病程相关,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.bone_symptoms.pathological_fractures.common_sites,椎体压缩骨折; 髋部骨折; 前臂骨折; 肋骨骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.bone_symptoms.pathological_fractures.healing,骨折愈合可能延迟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.bone_symptoms.pathological_fractures.prevention,及时治疗甲状旁腺功能亢进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.bone_symptoms.joint_symptoms.arthralgia,关节疼痛,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.bone_symptoms.joint_symptoms.chondrocalcinosis,软骨钙化症（假痛风）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.bone_symptoms.joint_symptoms.gout,继发性痛风（高钙抑制尿酸排泄）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.brown_tumor_manifestations.locations_and_symptoms.maxillofacial.sites,颌骨、上颌窦,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.brown_tumor_manifestations.locations_and_symptoms.maxillofacial.symptoms,面部肿胀、牙齿松动、咀嚼困难,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.brown_tumor_manifestations.locations_and_symptoms.extremities.sites,股骨、胫骨、桡骨,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.brown_tumor_manifestations.locations_and_symptoms.extremities.symptoms,局部肿胀、疼痛、功能障碍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.brown_tumor_manifestations.locations_and_symptoms.axial_skeleton.sites,脊椎、肋骨、骨盆,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.brown_tumor_manifestations.locations_and_symptoms.axial_skeleton.symptoms,背痛、胸痛、神经压迫症状,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.brown_tumor_manifestations.differential_diagnosis,原发性骨肿瘤; 转移性骨病; 感染性骨病; 血管瘤,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.systemic_manifestations.hypercalcemia_symptoms.neuropsychiatric,抑郁、焦虑; 记忆力减退; 人格改变; 意识模糊; 昏迷（严重时）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.systemic_manifestations.hypercalcemia_symptoms.neuromuscular,肌无力; 疲乏; 肌肉萎缩; 反射减弱,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.systemic_manifestations.hypercalcemia_symptoms.gastrointestinal,食欲不振; 恶心呕吐; 便秘; 腹痛; 消化性溃疡,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.systemic_manifestations.hypercalcemia_symptoms.cardiovascular,心律失常; QT间期缩短; 高血压; 心肌收缩力增强,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.systemic_manifestations.hypercalcemia_symptoms.renal,多尿、烦渴; 肾结石; 肾功能不全; 肾钙化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.laboratory_abnormalities.calcium_elevation,血钙>2.65mmol/L,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.laboratory_abnormalities.phosphate_decrease,血磷通常降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.laboratory_abnormalities.pth_elevation,PTH显著升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,clinical_manifestations.laboratory_abnormalities.alkaline_phosphatase,反映骨转换增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.primary_tests.serum_calcium.measurement,总钙或离子钙,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.primary_tests.serum_calcium.correction,按白蛋白水平校正,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.primary_tests.serum_calcium.elevation,持续性高钙血症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.primary_tests.parathyroid_hormone.assay,完整PTH（iPTH）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.primary_tests.parathyroid_hormone.interpretation,高钙血症时PTH不抑制或升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.primary_tests.parathyroid_hormone.normal_reference,根据实验室参考值,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.primary_tests.serum_phosphate.pattern,通常降低或正常低值,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.primary_tests.serum_phosphate.mechanism,PTH促进肾脏磷排泄,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.primary_tests.25_hydroxyvitamin_d.importance,排除维生素D缺乏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.primary_tests.25_hydroxyvitamin_d.target_level,>75nmol/L (30ng/mL),ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.additional_tests.24h_urine_calcium.purpose,鉴别FHH与原发性甲状旁腺功能亢进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.additional_tests.24h_urine_calcium.calcium_creatinine_clearance_ratio,FHH时<0.01,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.additional_tests.bone_turnover_markers.formation_markers,PINP、骨钙蛋白升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.biochemical_diagnosis.additional_tests.bone_turnover_markers.resorption_markers,CTX、NTX升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_imaging.conventional_radiography.classic_findings,骨膜下皮质骨吸收; 褐色瘤; 普遍性骨质疏松; 病理性骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_imaging.conventional_radiography.specific_sites,手指骨桡侧面; 锁骨远端; 骶髂关节; 牙槽骨,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_imaging.bone_densitometry.pattern,皮质骨丢失>松质骨,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_imaging.bone_densitometry.sites,前臂（1/3桡骨）最明显,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_imaging.bone_densitometry.monitoring,治疗后骨密度改善,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_imaging.bone_scintigraphy.findings,弥漫性摄取增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_imaging.bone_scintigraphy.brown_tumors,局灶性摄取增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.bone_imaging.bone_scintigraphy.superscan,严重病例可见,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.indications,确诊后术前定位,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.ultrasound.sensitivity,腺瘤80-90%，增生较低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.ultrasound.operator_dependent,操作者依赖性强,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.ultrasound.limitations,胸骨后病变难以显示,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.sestamibi_scan.mechanism,甲状旁腺细胞线粒体摄取,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.sestamibi_scan.sensitivity,单腺体病变>80%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.sestamibi_scan.limitations,多腺体病变敏感性降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.4d_ct.advantages,高分辨率，多期扫描,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.4d_ct.sensitivity,90%以上,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.4d_ct.radiation,辐射暴露相对高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.mri.indications,其他检查阴性时,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.imaging_studies.parathyroid_localization.mri.advantages,无辐射，软组织对比好,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.genetic_testing.indications,年龄<40岁; 多腺体病变; 家族史阳性; 伴发其他内分泌肿瘤,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.genetic_testing.genes_to_test,MEN1基因; RET基因（MEN2）; CASR基因（FHH）; CDKN1B基因（MEN4）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.differential_diagnosis.other_causes_hypercalcemia,恶性肿瘤（PTHrP分泌）; 肉芽肿性疾病; 维生素D中毒; 甲状腺功能亢进; 制动综合征; 药物引起,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,diagnosis.differential_diagnosis.familial_hypocalciuric_hypercalcemia.key_differences,尿钙排泄低; 家族史; 症状轻微; CASR基因突变,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.indications.absolute,症状性高钙血症; 血钙>2.85mmol/L; 年龄<50岁; 肾结石病史; T评分<-2.5; eGFR<60ml/min,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.indications.relative,无法长期随访; 患者要求手术; 高钙尿症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.surgical_approaches.minimally_invasive_parathyroidectomy.requirements,单腺体病变; 术前成功定位; 术中PTH监测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.surgical_approaches.minimally_invasive_parathyroidectomy.advantages,创伤小、恢复快、美容效果好,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.surgical_approaches.bilateral_neck_exploration.indications,多腺体病变; 术前定位失败; 家族性疾病; 再次手术,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.surgical_approaches.bilateral_neck_exploration.procedure,四腺体探查,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.surgical_approaches.parathyroid_hyperplasia_surgery.subtotal_parathyroidectomy,保留部分最正常腺体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.surgical_approaches.parathyroid_hyperplasia_surgery.total_parathyroidectomy_with_autotransplant,全切除后前臂移植,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.intraoperative_monitoring.pth_monitoring.timing,切除病变腺体后10-15分钟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.intraoperative_monitoring.pth_monitoring.success_criteria,PTH下降>50%或至正常范围,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.intraoperative_monitoring.pth_monitoring.miami_criterion,最常用标准,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.intraoperative_monitoring.frozen_section,必要时病理冷冻切片,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.complications.temporary_complications,暂时性低钙血症; 暂时性声嘶; 血肿,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.complications.permanent_complications,永久性甲状旁腺功能减退症; 永久性声带麻痹; 甲状腺功能减退,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.surgical_treatment.complications.prevention,经验丰富的外科医生、术中神经监测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.perioperative_management.severe_hypercalcemia.fluid_resuscitation,生理盐水扩容,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.perioperative_management.severe_hypercalcemia.loop_diuretics,呋塞米促进钙排泄,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.perioperative_management.severe_hypercalcemia.bisphosphonates,唑来膦酸等抑制骨吸收,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.perioperative_management.severe_hypercalcemia.calcitonin,快速降钙作用,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.perioperative_management.preoperative_preparation.calcium_normalization,术前尽可能纠正高钙血症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.perioperative_management.preoperative_preparation.vitamin_d_repletion,补充维生素D至充足水平,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.perioperative_management.preoperative_preparation.cardiac_evaluation,评估心血管风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.non_surgical_candidates.calcimimetics.cinacalcet.mechanism,钙敏感受体激动剂,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.non_surgical_candidates.calcimimetics.cinacalcet.dosing,30-180mg/天,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.non_surgical_candidates.calcimimetics.cinacalcet.effects,降低PTH和血钙,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.non_surgical_candidates.calcimimetics.cinacalcet.side_effects,恶心、呕吐、低钙血症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.non_surgical_candidates.calcimimetics.etelcalcetide.indication,透析患者继发性甲状旁腺功能亢进,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.non_surgical_candidates.calcimimetics.etelcalcetide.administration,透析时静脉给药,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.non_surgical_candidates.bisphosphonates.mechanism,抑制破骨细胞活性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.non_surgical_candidates.bisphosphonates.agents,阿仑膦酸、唑来膦酸等,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.non_surgical_candidates.bisphosphonates.effects,改善骨密度，不影响PTH,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.non_surgical_candidates.bisphosphonates.monitoring,肾功能、颌骨坏死风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.chronic_kidney_disease.phosphate_binders,控制血磷水平,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.chronic_kidney_disease.active_vitamin_d,骨化三醇、帕立骨化醇,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.chronic_kidney_disease.calcimimetics,西那卡塞降低PTH,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.medical_treatment.chronic_kidney_disease.parathyroidectomy,药物治疗失败时,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.postoperative_management.calcium_monitoring.frequency,术后6小时开始，每6小时,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.postoperative_management.calcium_monitoring.duration,至少48小时,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.postoperative_management.calcium_monitoring.target,维持血钙正常下限,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.postoperative_management.hypocalcemia_management.oral_calcium,碳酸钙1-2g每4小时,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.postoperative_management.hypocalcemia_management.calcitriol,0.25-0.5μg每12小时,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.postoperative_management.hypocalcemia_management.intravenous_calcium,症状性低钙血症时,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.postoperative_management.hungry_bone_syndrome.definition,术后骨骼快速再矿化导致严重低钙血症,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.postoperative_management.hungry_bone_syndrome.risk_factors,术前严重骨病、高PTH、高ALP,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,treatment.postoperative_management.hungry_bone_syndrome.management,大量钙剂和活性维生素D补充,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,monitoring.postoperative_monitoring.short_term.parameters,血清钙; 血清磷; PTH; 症状评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,monitoring.postoperative_monitoring.short_term.frequency,1周、1个月、3个月、6个月,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,monitoring.postoperative_monitoring.short_term.success_criteria,血钙正常，PTH正常或适当抑制,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,monitoring.postoperative_monitoring.long_term.bone_density,术后1年复查，之后每1-2年,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,monitoring.postoperative_monitoring.long_term.renal_function,年度评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,monitoring.postoperative_monitoring.long_term.cardiovascular_risk,血压、血脂监测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,monitoring.non_surgical_monitoring.frequency,每3-6个月,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,monitoring.non_surgical_monitoring.parameters,血清钙; 肾功能; 骨密度（年度）; 肾结石筛查; 症状评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,monitoring.non_surgical_monitoring.intervention_triggers,血钙进一步升高; 出现症状; 骨密度显著下降; 肾功能恶化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.surgical_outcomes.cure_rates.single_adenoma,95-99%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.surgical_outcomes.cure_rates.multiple_adenomas,90-95%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.surgical_outcomes.cure_rates.hyperplasia,85-90%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.surgical_outcomes.bone_recovery.timeline,术后6-12个月开始,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.surgical_outcomes.bone_recovery.extent,T评分改善1-2个标准差,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.surgical_outcomes.bone_recovery.factors,年龄、术前骨病严重程度,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.surgical_outcomes.symptom_improvement.bone_pain,数周内开始缓解,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.surgical_outcomes.symptom_improvement.neuromuscular,数月内显著改善,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.surgical_outcomes.symptom_improvement.nephrolithiasis,复发风险显著降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.surgical_outcomes.symptom_improvement.neuropsychiatric,改善变异大,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.brown_tumor_resolution.timeline,术后6个月-2年,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.brown_tumor_resolution.mechanism,PTH正常后骨重塑恢复,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.brown_tumor_resolution.monitoring,影像学随访评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.complications_and_recurrence.recurrence_rate,<5%（单腺体病变）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.complications_and_recurrence.risk_factors,多腺体病变; 家族性疾病; 不完全切除; 异位甲状旁腺,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.complications_and_recurrence.long_term_monitoring,终身随访,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.quality_of_life.improvement_areas,骨痛缓解; 体力活动能力; 精神状态; 社会功能,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
BONE_003,BONE_003,甲状旁腺性骨病,,骨代谢疾病,骨代谢疾病,prognosis.quality_of_life.persistent_issues,部分神经精神症状可能持续; 严重骨病变可能不完全恢复,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,BONE_003.csv
NUTRI_002,NUTRI_002,代谢综合征,,营养代谢疾病,营养代谢疾病,pathophysiology.insulin_resistance.tissue_effects.muscle,骨骼肌糖摄取减少,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,NUTRI_002.csv
NUTRI_003,NUTRI_003,维生素D缺乏症,,营养代谢疾病,营养代谢疾病,pathophysiology.vitamin_d_metabolism.activation.kidney,"1α羟化酶生成1,25(OH)2D3（骨化三醇）",ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,NUTRI_003.csv
NUTRI_003,NUTRI_003,维生素D缺乏症,,营养代谢疾病,营养代谢疾病,pathophysiology.physiological_functions.bone_metabolism,促进骨基质矿化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,NUTRI_003.csv
NUTRI_003,NUTRI_003,维生素D缺乏症,,营养代谢疾病,营养代谢疾病,pathophysiology.deficiency_consequences.bone_demineralization,骨质疏松和骨软化,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,NUTRI_003.csv
NUTRI_003,NUTRI_003,维生素D缺乏症,,营养代谢疾病,营养代谢疾病,clinical_features.skeletal_manifestations.adults,骨痛、骨软化症、骨质疏松,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,NUTRI_003.csv
NUTRI_003,NUTRI_003,维生素D缺乏症,,营养代谢疾病,营养代谢疾病,clinical_features.skeletal_manifestations.children,佝偻病、骨骼畸形、生长迟缓,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,NUTRI_003.csv
NUTRI_003,NUTRI_003,维生素D缺乏症,,营养代谢疾病,营养代谢疾病,clinical_features.skeletal_manifestations.fracture_risk,脆性骨折风险增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,NUTRI_003.csv
REPRO_002,REPRO_002,男性性腺功能减退症,,生殖内分泌疾病,生殖内分泌疾病,pathophysiology.consequences.musculoskeletal,肌肉量减少、骨密度降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,REPRO_002.csv
REPRO_002,REPRO_002,男性性腺功能减退症,,生殖内分泌疾病,生殖内分泌疾病,clinical_features.physical_manifestations.body_composition.bone_density_loss,骨密度降低，骨折风险增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,REPRO_002.csv
REPRO_003,REPRO_003,卵巢早衰,,生殖内分泌疾病,生殖内分泌疾病,clinical_presentation.long_term_consequences.osteoporosis,骨质疏松和骨折风险增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,REPRO_003.csv
REPRO_003,REPRO_003,卵巢早衰,,生殖内分泌疾病,生殖内分泌疾病,management_approach.hormone_replacement.monitoring,定期评估症状、骨密度、心血管风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,REPRO_003.csv
REPRO_003,REPRO_003,卵巢早衰,,生殖内分泌疾病,生殖内分泌疾病,management_approach.bone_health.bisphosphonates,重度骨质疏松时考虑,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,REPRO_003.csv
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.imaging.bone_density,骨密度检测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_007.csv
RHEUM_008,RHEUM_008,多腺体自身免疫综合征II型 (APS-2),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.associated_conditions.primary_hypogonadism.manifestations,闭经，不孕; 性欲减退; 骨质疏松; 潮热,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_008.csv
RHEUM_008,RHEUM_008,多腺体自身免疫综合征II型 (APS-2),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.imaging_studies.bone_density,DEXA骨密度检测（激素缺乏继发）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_008.csv
RHEUM_008,RHEUM_008,多腺体自身免疫综合征II型 (APS-2),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.supportive_therapy.vitamin_supplementation.vitamin_d,骨健康维护,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_008.csv
RHEUM_008,RHEUM_008,多腺体自身免疫综合征II型 (APS-2),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.supportive_therapy.vitamin_supplementation.calcium,骨质疏松预防,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_008.csv
RHEUM_008,RHEUM_008,多腺体自身免疫综合征II型 (APS-2),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.monitoring_protocol.complication_surveillance.bone_health,骨密度定期检测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_008.csv
RHEUM_008,RHEUM_008,多腺体自身免疫综合征II型 (APS-2),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,prognosis.overall_outlook.complications,肾上腺危象; 糖尿病并发症; 骨质疏松; 心血管疾病; 感染易感性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_008.csv
RHEUM_009,RHEUM_009,痛风,,晶体性关节病,晶体性关节病,clinical_manifestations.chronic_gout.chronic_arthropathy.joint_destruction.mechanism,尿酸盐结晶引起软骨和骨质破坏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_009.csv
RHEUM_009,RHEUM_009,痛风,,晶体性关节病,晶体性关节病,clinical_manifestations.chronic_gout.chronic_arthropathy.joint_destruction.imaging_features,关节间隙狭窄; 骨质糜烂; 痛风石影; 关节畸形,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_009.csv
RHEUM_009,RHEUM_009,痛风,,晶体性关节病,晶体性关节病,diagnosis.imaging_studies.conventional_radiography.chronic_changes,关节间隙狭窄; 骨质糜烂（punched-out病变）; 痛风石软组织影; 关节畸形,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_009.csv
RHEUM_009,RHEUM_009,痛风,,晶体性关节病,晶体性关节病,diagnosis.imaging_studies.mri.indications,评估深部痛风石和骨髓水肿,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,RHEUM_009.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,name_en,Osteoporosis,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,description,以骨量减少、骨组织微结构破坏为特征的全身性骨病,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,icd_10,M80-M81,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.prevalence_postmenopausal,50岁以上女性19.2%,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.prevalence_elderly_men,65岁以上男性13.0%,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.fracture_risk,髋部骨折终生风险女性13%，男性4%,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.economic_burden,年医疗费用超过190亿元,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.postmenopausal.type,I型骨质疏松,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.postmenopausal.mechanism,雌激素缺乏,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.postmenopausal.onset,绝经后5-10年,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.postmenopausal.bone_loss_rate,每年2-5%,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.senile.type,II型骨质疏松,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.senile.mechanism,年龄相关骨丢失,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.senile.onset,70岁以后,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.primary.senile.characteristics,皮质骨和松质骨均受累,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.secondary.endocrine,甲状腺功能亢进; 甲状旁腺功能亢进; 库欣综合征; 性腺功能减退,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.secondary.medications,糖皮质激素; 抗癫痫药物; 芳香化酶抑制剂; GnRH激动剂,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,classification.secondary.diseases,类风湿关节炎; 炎症性肠病; 慢性肾病; 恶性肿瘤,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.bone_remodeling_imbalance.normal_remodeling,骨形成与骨吸收平衡,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.bone_remodeling_imbalance.osteoporosis,骨吸收 > 骨形成,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.bone_remodeling_imbalance.cellular_mechanism,破骨细胞活性增加，成骨细胞功能减退,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.hormonal_factors.estrogen_deficiency,雌激素缺乏导致RANKL/OPG比值升高,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.hormonal_factors.pth_excess,继发性甲旁亢加速骨丢失,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.hormonal_factors.vitamin_d_deficiency,影响钙吸收和骨矿化,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mechanical_factors.disuse,缺乏负重运动,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mechanical_factors.immobilization,长期卧床,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mechanical_factors.microgravity,失重环境,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.asymptomatic_phase.duration,数年至数十年,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.asymptomatic_phase.characteristics,无症状骨量丢失,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.asymptomatic_phase.detection,仅通过骨密度检测发现,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.bone_pain.location,腰背部最常见,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.bone_pain.characteristics,持续性钝痛,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.bone_pain.aggravating_factors,活动后加重,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.vertebral.prevalence,最常见骨折类型,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.vertebral.symptoms,急性背痛，身高缩短,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.vertebral.complications,脊柱畸形，肺功能受损,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.hip.mortality,1年死亡率15-20%,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.hip.morbidity,50%患者不能独立行走,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.hip.economic_impact,医疗费用最高,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.distal_radius.onset,绝经早期常见,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.distal_radius.mechanism,跌倒时手掌撑地,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.fractures.distal_radius.recovery,相对较好,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.kyphosis.cause,椎体压缩性骨折,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.kyphosis.appearance,驼背畸形,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.symptomatic_phase.kyphosis.functional_impact,呼吸功能受限,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.gold_standard,双能X线吸收测定法,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.sites,腰椎L1-L4; 股骨颈; 全髋,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.t_score_interpretation.normal,T评分 ≥ -1.0,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.t_score_interpretation.osteopenia,T评分 -1.0 到 -2.5,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.t_score_interpretation.osteoporosis,T评分 ≤ -2.5,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.dexa_scan.t_score_interpretation.severe_osteoporosis,T评分 ≤ -2.5 + 脆性骨折,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.qct.method,定量CT,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.qct.advantage,真正的体积骨密度,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.qct.limitation,辐射剂量较高,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.peripheral_devices.pdexa,外周双能X线,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.peripheral_devices.qus,定量超声,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.bone_density_measurement.peripheral_devices.use,筛查工具,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_formation.osteocalcin,骨钙素,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_formation.p1np,I型前胶原氨基端肽,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_formation.balp,骨特异性碱性磷酸酶,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_resorption.ctx,I型胶原羧基端肽,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_resorption.ntx,I型胶原氨基端肽,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.bone_resorption.trap_5b,抗酒石酸酸性磷酸酶5b,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.biochemical_markers.clinical_utility,监测治疗反应; 评估骨转换状态; 预测骨折风险,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.fracture_risk_assessment.frax_tool.components,年龄、性别、BMI; 既往骨折史; 父母髋部骨折史; 吸烟、饮酒; 糖皮质激素使用; 类风湿关节炎; 继发性骨质疏松原因; 股骨颈骨密度,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.fracture_risk_assessment.frax_tool.output,10年髋部骨折和主要骨折风险,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.fracture_risk_assessment.qfracture,英国骨折风险评估工具,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,diagnostic_methods.fracture_risk_assessment.garvan,澳大利亚骨折风险计算器,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.nutrition.calcium,每日1000-1200mg,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.nutrition.vitamin_d,800-1000IU/日,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.nutrition.protein,每日1.0-1.2g/kg体重,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.nutrition.limitations,避免过量咖啡因、钠盐,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.exercise.weight_bearing,负重有氧运动,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.exercise.resistance_training,阻力训练,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.exercise.balance_training,平衡训练预防跌倒,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.exercise.frequency,每周至少3-4次,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.fall_prevention.environmental,移除家中危险因素,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.fall_prevention.vision_correction,视力矫正,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.fall_prevention.medication_review,评估致跌倒药物,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.lifestyle_interventions.fall_prevention.assistive_devices,使用辅助器具,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.alendronate.dose,阿仑膦酸钠 70mg/周,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.alendronate.administration,空腹服用，服后直立30分钟,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.alendronate.efficacy,椎体骨折风险降低40-50%,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.risedronate.dose,利塞膦酸钠 35mg/周,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.risedronate.advantage,胃肠道耐受性好,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.risedronate.efficacy,髋部骨折风险降低30%,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.ibandronate.dose,伊班膦酸钠 150mg/月,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.ibandronate.route,口服或静脉注射,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.ibandronate.convenience,给药频率低,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.zoledronic_acid.dose,唑来膦酸 5mg/年,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.zoledronic_acid.route,静脉滴注,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.first_line.bisphosphonates.zoledronic_acid.efficacy,最强的抗骨折效果,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.denosumab.mechanism,RANKL抗体,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.denosumab.dose,地诺单抗 60mg/6个月 皮下注射,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.denosumab.efficacy,椎体骨折风险降低68%,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.denosumab.consideration,停药后骨量快速丢失,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.teriparatide.mechanism,重组PTH(1-34),Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.teriparatide.dose,特立帕肽 20μg/日 皮下注射,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.teriparatide.duration,最多2年,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.teriparatide.indication,严重骨质疏松症,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.abaloparatide.mechanism,PTHrP类似物,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.abaloparatide.dose,阿巴洛帕肽 80μg/日,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.second_line.abaloparatide.advantage,较少高钙血症风险,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.postmenopausal.estrogen,雌激素替代治疗,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.postmenopausal.indication,绝经期症状明显,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.postmenopausal.risks,血栓、乳腺癌风险,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.selective_modulators.raloxifene,雷洛昔芬 60mg/日,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.selective_modulators.benefit,预防椎体骨折和乳腺癌,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.pharmacological_treatment.hormone_therapy.selective_modulators.limitation,不预防髋部骨折,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.monitoring.bone_density,治疗后1-2年复查DXA,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.monitoring.biochemical_markers,治疗后3-6个月检测,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.monitoring.clinical_assessment,定期评估疼痛和功能,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.monitoring.safety_monitoring,监测药物不良反应,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,complications.fracture_complications.vertebral,慢性疼痛; 脊柱畸形; 功能障碍,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,complications.fracture_complications.hip,深静脉血栓; 肺栓塞; 死亡,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,complications.fracture_complications.general,感染; 褥疮; 肌肉萎缩,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,complications.medication_related.bisphosphonates,上消化道刺激; 下颌骨坏死(罕见); 非典型股骨骨折(极罕见),Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,complications.medication_related.denosumab,低钙血症; 感染风险增加; 停药后骨折风险反弹,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.with_treatment,骨折风险显著降低,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.fracture_healing,愈合能力基本正常,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.quality_of_life,疼痛减轻，功能改善,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_001,骨质疏松症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.life_expectancy,早期诊断治疗预后良好,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,name_en,Osteomalacia,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,description,成人维生素D缺乏或代谢异常导致的骨矿化障碍,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,icd_10,M83,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.prevalence,维生素D缺乏患者中10-15%,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.risk_populations,老年人群; 日照不足地区; 室内工作者; 穿着遮体服装人群,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,epidemiology.geographic_distribution,高纬度地区高发,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_deficiency.inadequate_sunlight,日照不足,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_deficiency.dietary_insufficiency,膳食摄入不足,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_deficiency.malabsorption,吸收不良综合征,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_deficiency.chronic_kidney_disease,慢性肾病,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_metabolism_disorders.1_alpha_hydroxylase_deficiency,1α-羟化酶缺陷,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_metabolism_disorders.vitamin_d_receptor_defects,维生素D受体缺陷,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.vitamin_d_metabolism_disorders.24_hydroxylase_excess,24-羟化酶过度活跃,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.phosphate_deficiency.hereditary_hypophosphatemia,遗传性低磷血症,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.phosphate_deficiency.tumor_induced,肿瘤诱发性骨软化症,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.phosphate_deficiency.fanconi_syndrome,Fanconi综合征,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,etiology.drug_induced,抗癫痫药物; 糖皮质激素; 铝制剂; 氟化物过量,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mineralization_defect.mechanism,骨基质正常，矿化不足,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mineralization_defect.histology,增宽的骨样组织缝,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.mineralization_defect.biochemistry,钙磷乘积不足,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.secondary_hyperparathyroidism.trigger,低钙血症或维生素D缺乏,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.secondary_hyperparathyroidism.consequences,PTH升高，骨转换增加,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.secondary_hyperparathyroidism.bone_effects,骨吸收增加,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.muscle_effects.weakness,近端肌无力,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.muscle_effects.mechanism,维生素D受体缺陷,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,pathophysiology.muscle_effects.recovery,补充维生素D后改善,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.bone_pain.characteristics,弥漫性钝痛,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.bone_pain.location,腰背部、髋部、胸肋部,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.bone_pain.timing,休息时也存在,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.tenderness,骨压痛，尤其是胸骨,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.fractures,假性骨折(Looser带),Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.bone_symptoms.deformities,严重时出现骨骼变形,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.muscle_symptoms.proximal_weakness,近端肌群无力,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.muscle_symptoms.myalgia,肌肉疼痛,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.muscle_symptoms.difficulty_walking,行走困难,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.muscle_symptoms.falls,跌倒风险增加,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.systemic_symptoms.fatigue,疲劳乏力,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.systemic_symptoms.depression,抑郁情绪,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.systemic_symptoms.cognitive_impairment,认知功能下降,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,clinical_manifestations.systemic_symptoms.increased_infections,感染易感性增加,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.vitamin_d_status.25_oh_d3,<30nmol/L (严重缺乏),Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.vitamin_d_status.1_25_oh2_d3,可正常或降低,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.vitamin_d_status.optimal_level,25(OH)D3 >75nmol/L,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.calcium_phosphate.serum_calcium,正常或轻度降低,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.calcium_phosphate.serum_phosphate,正常或降低,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.calcium_phosphate.ionized_calcium,可能降低,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.parathyroid_function.pth,升高(继发性甲旁亢),Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.parathyroid_function.correlation,与25(OH)D3水平负相关,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.bone_turnover_markers.alkaline_phosphatase,升高,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.bone_turnover_markers.osteocalcin,可升高,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,laboratory_findings.bone_turnover_markers.ctx,可升高,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.x_ray.pseudofractures,Looser带(假性骨折线),Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.x_ray.common_sites,股骨颈; 耻骨支; 肋骨,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.x_ray.osteopenia,弥漫性骨量减少,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.bone_scan.hotspots,Looser带处放射性摄取增加,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.bone_scan.pattern,多发性热点,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.bone_biopsy.indication,诊断困难时,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.bone_biopsy.findings,增宽的骨样组织缝,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,imaging_findings.bone_biopsy.gold_standard,确诊的金标准,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.cholecalciferol.loading_dose,"维生素D3 50,000IU/周 × 8周",Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.cholecalciferol.maintenance,800-2000IU/日,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.cholecalciferol.monitoring,治疗后6-8周检测25(OH)D3,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.ergocalciferol.dose,"维生素D2 50,000IU/周",Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.ergocalciferol.efficacy,较维生素D3稍差,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.active_metabolites.calcitriol,骨化三醇 0.25-1μg/日,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.active_metabolites.alfacalcidol,阿法骨化醇 0.5-2μg/日,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.vitamin_d_supplementation.active_metabolites.indication,肾功能不全患者,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.calcium_supplementation.elemental_calcium,1000-1500mg/日,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.calcium_supplementation.timing,与维生素D同服,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.calcium_supplementation.monitoring,避免过量补充,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.phosphate_supplementation.indication,低磷血症患者,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.phosphate_supplementation.dose,磷酸盐 1-3g/日 分次服用,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.phosphate_supplementation.monitoring,血磷、PTH水平,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.supportive_treatment.sun_exposure,增加日光照射,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.supportive_treatment.dietary_modification,富含维生素D食物,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.supportive_treatment.physical_therapy,肌力训练,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,treatment.supportive_treatment.fall_prevention,预防跌倒措施,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,monitoring.biochemical,25(OH)D3 每3-6个月; 血钙、磷、PTH; 肾功能; 骨转换标志物,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,monitoring.clinical,疼痛评估; 肌力测试; 步态分析; 跌倒风险评估,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,monitoring.imaging,骨密度(DXA); 必要时重复X线检查,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.with_treatment,症状明显改善,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.bone_healing,假性骨折可愈合,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.muscle_recovery,肌无力逐渐恢复,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
bone_metabolism_entities,BONE_002,骨软化症,,metabolic_bone_disease,bone_metabolism_disorder,prognosis.prevention,适当补充可完全预防,Endocrine Society Growth Hormone Guidelines 2024,bone_metabolism_entities.csv
cerebrovascular_diseases,RHEUM_003,艾迪生病,,Disease,自身免疫性内分泌疾病,complications.overtreatment.glucocorticoid_excess,库欣样表现; 骨质疏松; 糖尿病; 高血压,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_004,系统性红斑狼疮,,Disease,系统性风湿病,treatment.pharmacotherapy.corticosteroids.side_effects,感染风险; 骨质疏松; 糖尿病; 心血管疾病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_004,系统性红斑狼疮,,Disease,系统性风湿病,treatment.supportive_care.bone_health,钙剂和维生素D补充; 双磷酸盐预防骨质疏松,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_004,系统性红斑狼疮,,Disease,系统性风湿病,complications.treatment_related,感染（机会性感染）; 骨质疏松和骨折; 药物性糖尿病; 心血管疾病加速; 性腺功能损害,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,pathophysiology.autoimmune_process.pannus_formation,血管翳形成并侵蚀软骨骨质,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,clinical_manifestations.endocrine_associations.bone_metabolism.osteoporosis.prevalence,明显高于正常人群,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,clinical_manifestations.endocrine_associations.bone_metabolism.osteoporosis.mechanisms,炎症因子直接作用; 糖皮质激素使用; 活动减少,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,clinical_manifestations.endocrine_associations.bone_metabolism.osteoporosis.fracture_risk,髋部骨折风险增加2倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,clinical_manifestations.endocrine_associations.bone_metabolism.bone_erosions,局部骨质破坏和全身骨丢失并存,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,diagnostics.laboratory_tests.bone_metabolism.alkaline_phosphatase,骨型ALP升高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,diagnostics.laboratory_tests.bone_metabolism.ctx_ntx,骨吸收标志物,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,diagnostics.laboratory_tests.bone_metabolism.p1np,骨形成标志物,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,diagnostics.imaging.conventional_radiography.progressive_changes,关节间隙狭窄、骨质疏松,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,diagnostics.imaging.conventional_radiography.advanced_changes,骨侵蚀、畸形、强直,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,diagnostics.imaging.ultrasound.bone_erosions,早期骨侵蚀检出,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,diagnostics.imaging.mri.bone_marrow_edema,骨髓水肿（炎症早期征象）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,diagnostics.imaging.mri.structural_damage,软骨和骨质破坏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,treatment.comorbidity_management.bone_health.osteoporosis_prevention,钙剂和维生素D; 双磷酸盐; 负重运动,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,treatment.comorbidity_management.bone_health.dexa_monitoring,骨密度定期评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_005,类风湿关节炎,,Disease,系统性风湿病,prognosis.prognostic_factors,抗CCP抗体阳性; 高疾病活动度; 关节外表现; 早期骨侵蚀,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,cerebrovascular_diseases.csv
entities.adrenal_entities,ADR_002,库欣综合征,,disease,肾上腺疾病,clinical_manifestations.metabolic_features,糖耐量异常/糖尿病; 高血压; 血脂异常; 骨质疏松,Endocrine Society Adrenal Guidelines 2024,entities_adrenal_entities.csv
entities.adrenal_entities,ADR_002,库欣综合征,,disease,肾上腺疾病,clinical_manifestations.central_obesity.features,向心性肥胖; 满月脸; 水牛背; 锁骨上脂肪垫,Endocrine Society Adrenal Guidelines 2024,entities_adrenal_entities.csv
entities.adrenal_entities,ADR_002,库欣综合征,,disease,肾上腺疾病,clinical_manifestations.metabolic_effects.osteoporosis,50%患者有骨质疏松,Endocrine Society Adrenal Guidelines 2024,entities_adrenal_entities.csv
entities.diabetes_complications,DM_COMP_002,糖尿病肾病,,complication,糖尿病微血管并发症,clinical_manifestations.advanced_stage,尿毒症症状; 贫血; 骨代谢异常; 心血管并发症,ADA Standards of Medical Care in Diabetes 2025,entities_diabetes_complications.csv
entities.diabetes_entities,DM_001,2型糖尿病,,disease,代谢性疾病,pathophysiology.insulin_resistance.primary_sites,肝脏; 骨骼肌; 脂肪组织,ADA Standards of Medical Care in Diabetes 2025,entities_diabetes_entities.csv
entities.diabetes_medications,DM_MED_004,SGLT-2抑制剂,,medication,钠-葡萄糖共转运蛋白抑制剂,drug_examples.canagliflozin.bone_effects,骨折风险可能增加,ADA Standards of Medical Care in Diabetes 2025,entities_diabetes_medications.csv
entities.endocrine_system_entities,HORM_001,睾酮,,hormone,性激素,properties.target_organs,前列腺; 骨骼肌; 骨骼; 毛囊; 中枢神经系统,International Society of Endocrinology Clinical Practice Guidelines,entities_endocrine_system_entities.csv
entities.endocrine_system_entities,HORM_001,睾酮,,hormone,性激素,properties.physiological_functions,男性第二性征发育; 精子生成; 肌肉和骨质量维持; 性欲调节; 认知功能影响,International Society of Endocrinology Clinical Practice Guidelines,entities_endocrine_system_entities.csv
entities.endocrine_system_entities,HORM_002,雌二醇,,hormone,性激素,properties.production_sites,卵巢颗粒细胞; 胎盘; 脂肪组织; 骨骼; 脑组织,International Society of Endocrinology Clinical Practice Guidelines,entities_endocrine_system_entities.csv
entities.endocrine_system_entities,HORM_002,雌二醇,,hormone,性激素,properties.physiological_functions,女性第二性征发育; 子宫内膜增殖; 骨量维持; 心血管保护; 神经保护作用,International Society of Endocrinology Clinical Practice Guidelines,entities_endocrine_system_entities.csv
entities.gonadal_entities,GON_002,男性性腺功能减退症,,disease,性腺疾病,clinical_manifestations.physical_symptoms,肌肉量和力量减少; 骨密度降低; 体脂增加; 乳房发育; 体毛减少; 面部潮红,American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.gonadal_entities,GON_002,男性性腺功能减退症,,disease,性腺疾病,complications.untreated_consequences,骨质疏松; 心血管疾病风险增加; 代谢综合征; 抑郁和生活质量下降; 不育,American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.gonadal_entities,GON_003,女性性腺功能减退症,,disease,性腺疾病,clinical_manifestations.long_term_consequences,骨质疏松; 心血管疾病风险增加; 认知功能下降; 情绪障碍,American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.gonadal_entities,GON_003,女性性腺功能减退症,,disease,性腺疾病,treatment_options.hormone_replacement_therapy.indications,症状明显; 年龄<60岁或绝经<10年; 骨质疏松预防,American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.gonadal_entities,GON_004,性早熟,,disease,性腺疾病,clinical_assessment.physical_examination,Tanner分期评估; 生长速度测量; 骨龄评估,American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.gonadal_entities,GON_004,性早熟,,disease,性腺疾病,clinical_assessment.laboratory_tests.imaging,骨龄X线; 盆腔/阴囊超声; 头颅MRI(中枢性),American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.gonadal_entities,GON_004,性早熟,,disease,性腺疾病,treatment_strategies.gnrh_agonist_therapy.monitoring,生长速度; 骨龄进展; 激素抑制效果,American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.gonadal_entities,GON_004,男性性腺功能减退症,,disease,性腺疾病,clinical_manifestations.physical_changes.decreased_bone_density,骨密度下降,American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.gonadal_entities,GON_004,男性性腺功能减退症,,disease,性腺疾病,monitoring.efficacy_parameters,症状改善; 睾酮水平; 血红蛋白; 骨密度,American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.gonadal_entities,GON_005,Turner综合征,,disease,性腺疾病,surveillance.bone_health,骨密度监测,American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.gonadal_entities,GON_006,Kallmann综合征,,disease,性腺疾病,clinical_manifestations.reproductive_dysfunction.females.osteoporosis,骨质疏松,American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,entities_gonadal_entities.csv
entities.pituitary_entities,PIT_002,泌乳素瘤,,disease,垂体疾病,clinical_manifestations.hyperprolactinemia_effects.women,月经紊乱/闭经; 不孕; 溢乳; 性欲减退; 骨质疏松,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_002,泌乳素瘤,,disease,垂体疾病,clinical_manifestations.hyperprolactinemia_effects.men,性功能减退; 阳痿; 不育; 溢乳(少见); 骨质疏松,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_003,肢端肥大症,,disease,垂体疾病,description,生长激素分泌过多导致的慢性进行性疾病，特征为骨骼、软组织过度生长,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_004,生长激素缺乏症,,disease,垂体疾病,classification.childhood_ghd.manifestations,生长发育迟缓; 身材矮小; 骨龄落后; 低血糖倾向,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_004,生长激素缺乏症,,disease,垂体疾病,classification.adult_ghd.manifestations,体脂增加; 肌肉量减少; 骨密度降低; 运动耐量下降; 生活质量下降,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_004,肢端肥大症,,disease,垂体疾病,pathophysiology.tissue_growth,软组织、骨骼、内脏器官增生,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_004,肢端肥大症,,disease,垂体疾病,clinical_manifestations.skeletal_changes.acral_enlargement.skull,颅骨增厚、枕外隆突明显,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_004,肢端肥大症,,disease,垂体疾病,monitoring.complication_screening,心脏超声; 睡眠呼吸监测; 结肠镜检查; 骨密度检测,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_005,垂体功能减退症,,disease,垂体疾病,hormonal_deficiencies.growth_hormone_deficiency.adults.symptoms,乏力; 肌肉量减少; 骨密度下降; 腹部脂肪增加; 生活质量下降,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_005,垂体功能减退症,,disease,垂体疾病,hormonal_deficiencies.gonadotropin_deficiency.males.symptoms,性欲减退; 勃起功能障碍; 肌肉量减少; 骨质疏松,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_005,垂体功能减退症,,disease,垂体疾病,hormonal_deficiencies.gonadotropin_deficiency.females.symptoms,闭经; 不孕; 潮热; 骨质疏松,Endocrine Society Pituitary Guidelines 2024,entities_pituitary_entities.csv
entities.thyroid_entities,THY_004,亚临床甲状腺功能异常,,disease,甲状腺疾病,subtypes.subclinical_hyperthyroidism.risks,心房颤动; 骨质疏松; 全因死亡率增加,American Thyroid Association Guidelines 2025,entities_thyroid_entities.csv
entities.thyroid_entities,THY_005,甲状腺癌,,neoplasm,甲状腺疾病,treatment_approach.tsh_suppression.monitoring,甲功、心脏、骨密度,American Thyroid Association Guidelines 2025,entities_thyroid_entities.csv
female_endocrine_entities,FEM_002,绝经期综合征,,reproductive_endocrine_disorder,female_endocrine_disease,pathophysiology.estrogen_deficiency_effects.bone_metabolism,骨吸收增加,North American Menopause Society Position Statement 2024,female_endocrine_entities.csv
female_endocrine_entities,FEM_002,绝经期综合征,,reproductive_endocrine_disorder,female_endocrine_disease,treatment.hormone_therapy.systemic_ht.indications,中重度血管舒缩症状; 泌尿生殖道症状; 骨质疏松预防,North American Menopause Society Position Statement 2024,female_endocrine_entities.csv
female_endocrine_entities,FEM_002,绝经期综合征,,reproductive_endocrine_disorder,female_endocrine_disease,monitoring.long_term_health,骨密度检测; 心血管风险评估; 癌症筛查; 认知功能评估,North American Menopause Society Position Statement 2024,female_endocrine_entities.csv
female_endocrine_entities,FEM_002,绝经期综合征,,reproductive_endocrine_disorder,female_endocrine_disease,long_term_health_consequences.bone_health.bone_loss,绝经后5年内骨量丢失20%,North American Menopause Society Position Statement 2024,female_endocrine_entities.csv
female_endocrine_entities,FEM_002,绝经期综合征,,reproductive_endocrine_disorder,female_endocrine_disease,long_term_health_consequences.bone_health.fracture_risk,髋部骨折风险显著增加,North American Menopause Society Position Statement 2024,female_endocrine_entities.csv
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,clinical_manifestations.physical_signs,肌肉量减少; 骨密度降低; 体脂增加; 胡须和体毛稀少; 睾丸萎缩,American Urological Association Male Hypogonadism Guidelines 2024,male_endocrine_entities.csv
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,clinical_manifestations.metabolic_effects,胰岛素抵抗; 血脂异常; 骨质疏松; 贫血,American Urological Association Male Hypogonadism Guidelines 2024,male_endocrine_entities.csv
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,treatment.monitoring.efficacy,症状改善; 睾酮水平; 骨密度; 肌肉量,American Urological Association Male Hypogonadism Guidelines 2024,male_endocrine_entities.csv
male_endocrine_entities,MAL_001,男性性腺功能减退症,,reproductive_endocrine_disorder,male_endocrine_disease,complications.untreated_consequences,骨质疏松和骨折; 心血管疾病风险增加; 代谢综合征; 抑郁和认知功能下降; 不育,American Urological Association Male Hypogonadism Guidelines 2024,male_endocrine_entities.csv
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,clinical_manifestations.physical_changes,肌肉量减少; 腹部脂肪增加; 骨密度下降; 体毛减少,American Urological Association Male Hypogonadism Guidelines 2024,male_endocrine_entities.csv
male_endocrine_entities,MAL_002,男性更年期综合征,,age_related_endocrine_disorder,male_endocrine_disease,monitoring.safety_monitoring,前列腺检查; 心血管风险因子; 骨密度检测; 血液学检查,American Urological Association Male Hypogonadism Guidelines 2024,male_endocrine_entities.csv
metadata,coverage_areas,,,,,value,糖尿病及代谢性疾病; 甲状腺疾病; 肾上腺疾病; 垂体疾病; 高血压; 血脂异常; 肥胖症; 骨代谢疾病; 性腺疾病; 多发性内分泌肿瘤综合征,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,metadata.csv
nutrition_endocrine_entities,NUT_001,维生素D缺乏症,,nutritional_disorder,nutrition_endocrine_disease,pathophysiology.deficiency_effects.bone_mineralization,骨矿化障碍,International Society of Endocrinology Clinical Practice Guidelines,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_001,维生素D缺乏症,,nutritional_disorder,nutrition_endocrine_disease,clinical_manifestations.skeletal_effects.children,佝偻病; 骨骼畸形; 生长发育迟缓; 牙齿萌出延迟,International Society of Endocrinology Clinical Practice Guidelines,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_001,维生素D缺乏症,,nutritional_disorder,nutrition_endocrine_disease,clinical_manifestations.skeletal_effects.adults,骨软化症; 骨质疏松; 病理性骨折; 骨痛,International Society of Endocrinology Clinical Practice Guidelines,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_001,维生素D缺乏症,,nutritional_disorder,nutrition_endocrine_disease,diagnosis.imaging.bone_density,DXA骨密度检测,International Society of Endocrinology Clinical Practice Guidelines,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_001,维生素D缺乏症,,nutritional_disorder,nutrition_endocrine_disease,diagnosis.imaging.x_ray,骨骼X线检查,International Society of Endocrinology Clinical Practice Guidelines,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_001,维生素D缺乏症,,nutritional_disorder,nutrition_endocrine_disease,diagnosis.imaging.bone_biopsy,骨活检(极少需要),International Society of Endocrinology Clinical Practice Guidelines,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_001,维生素D缺乏症,,nutritional_disorder,nutrition_endocrine_disease,prognosis.bone_recovery,骨密度逐渐恢复,International Society of Endocrinology Clinical Practice Guidelines,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_001,维生素D缺乏症,,nutritional_disorder,nutrition_endocrine_disease,prognosis.prevention_benefits,显著降低骨折风险,International Society of Endocrinology Clinical Practice Guidelines,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_003,营养性甲状腺肿,,nutritional_disorder,nutrition_endocrine_disease,treatment.surgical_intervention.procedures,甲状腺大部切除; 甲状腺全切除; 胸骨下甲状腺肿切除,International Society of Endocrinology Clinical Practice Guidelines,nutrition_endocrine_entities.csv
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,clinical_manifestations.other_complications.osteoarthritis,骨关节炎,ADA Standards of Medical Care in Diabetes 2025,obesity_metabolic_entities.csv
obesity_metabolic_entities,OBE_002,代谢综合征,,metabolic_disorder,nutrition_metabolic_disease,pathophysiology.insulin_resistance.tissue_effects.muscle,骨骼肌糖摄取减少,ADA Standards of Medical Care in Diabetes 2025,obesity_metabolic_entities.csv
obesity_metabolic_entities,OBE_003,胰岛素抵抗综合征,,metabolic_disorder,nutrition_metabolic_disease,treatment.insulin_sensitizers.pioglitazone.side_effects,体重增加，水肿，骨折风险,ADA Standards of Medical Care in Diabetes 2025,obesity_metabolic_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,clinical_manifestations.skeletal_symptoms.bone_pain,骨痛，尤其是腰背部,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,clinical_manifestations.skeletal_symptoms.osteoporosis,骨质疏松症,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,clinical_manifestations.skeletal_symptoms.fractures,病理性骨折,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,laboratory_findings.alkaline_phosphatase,可升高，反映骨转换增加,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,imaging_studies.bone_density.dexa_scan,骨密度降低,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,imaging_studies.bone_density.preferred_sites,腰椎; 股骨颈; 前臂远端,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,imaging_studies.bone_density.t_score,T评分 < -2.5提示骨质疏松,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,treatment.surgical_treatment.indications,有症状的原发性甲旁亢; 无症状但符合手术指征; 血钙 >2.85mmol/L; 年龄 <50岁; 骨密度T评分 < -2.5; 肾功能减退(eGFR<60); 24小时尿钙 >10mmol,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,treatment.medical_management.bisphosphonates.indication,骨质疏松症,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,treatment.medical_management.monitoring,血钙、磷、PTH每3-6个月; 骨密度每1-2年; 肾功能每年; 影像学评估,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,complications.chronic.osteoporosis,骨质疏松性骨折,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_001,原发性甲状旁腺功能亢进症,,endocrine_disorder,parathyroid_disease,prognosis.bone_recovery,骨密度术后1-2年明显改善,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_003,假性甲状旁腺功能减退症,,genetic_disorder,parathyroid_disease,classification.type_1a.aho_features,Albright遗传性骨营养不良,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_003,假性甲状旁腺功能减退症,,genetic_disorder,parathyroid_disease,clinical_manifestations.aho_phenotype.subcutaneous_ossification,皮下骨化,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_003,假性甲状旁腺功能减退症,,genetic_disorder,parathyroid_disease,treatment.calcium_phosphate_management.calcitriol,骨化三醇 0.5-3μg/日,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_003,假性甲状旁腺功能减退症,,genetic_disorder,parathyroid_disease,monitoring.clinical,生长发育评估; 神经发育评估; 心血管检查; 骨密度检测,Endocrine Society Clinical Practice Guidelines,parathyroid_calcium_entities.csv
pediatric_endocrine_entities,PED_001,儿童生长激素缺乏症,,endocrine_disorder,pediatric_endocrine_disease,pathophysiology.growth_effects.linear_growth,骨骺软骨增殖,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_001,儿童生长激素缺乏症,,endocrine_disorder,pediatric_endocrine_disease,pathophysiology.deficiency_consequences.bone_maturation,骨龄延迟,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_001,儿童生长激素缺乏症,,endocrine_disorder,pediatric_endocrine_disease,clinical_manifestations.metabolic_manifestations.reduced_bone_density,骨密度降低,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_001,儿童生长激素缺乏症,,endocrine_disorder,pediatric_endocrine_disease,diagnostic_evaluation.auxological_assessment.bone_age,骨龄测定,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_001,儿童生长激素缺乏症,,endocrine_disorder,pediatric_endocrine_disease,diagnostic_evaluation.imaging_studies.bone_age.findings,骨龄明显延迟,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_001,儿童生长激素缺乏症,,endocrine_disorder,pediatric_endocrine_disease,treatment.growth_hormone_therapy.indications,确诊GH缺乏; 生长速度<4cm/年; 骨龄明显延迟; IGF-1持续低水平,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_001,儿童生长激素缺乏症,,endocrine_disorder,pediatric_endocrine_disease,treatment.growth_hormone_therapy.monitoring.bone_age,每年评估骨龄进展,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_001,儿童生长激素缺乏症,,endocrine_disorder,pediatric_endocrine_disease,monitoring_and_follow_up.laboratory_monitoring,IGF-1每6个月; 甲状腺功能每年; 糖化血红蛋白; 骨代谢标志物,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_001,儿童生长激素缺乏症,,endocrine_disorder,pediatric_endocrine_disease,monitoring_and_follow_up.imaging_follow_up,骨龄每年; 垂体MRI(如有指征); 脊柱X线(监测侧弯),Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_001,儿童生长激素缺乏症,,endocrine_disorder,pediatric_endocrine_disease,complications.untreated_consequences,成人矮小症; 心理社会问题; 代谢异常; 骨质疏松; 心血管风险增加,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_002,儿童甲状腺疾病,,endocrine_disorder,pediatric_endocrine_disease,clinical_manifestations.congenital_hypothyroidism.later_manifestations,生长发育迟缓; 智力发育障碍; 骨龄延迟; 牙齿萌出延迟,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_002,儿童甲状腺疾病,,endocrine_disorder,pediatric_endocrine_disease,clinical_manifestations.acquired_hypothyroidism.growth_effects,生长速度减慢; 青春期延迟; 骨龄延迟,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_002,儿童甲状腺疾病,,endocrine_disorder,pediatric_endocrine_disease,monitoring.growth_development,身高体重每3个月; 头围(婴儿); 骨龄评估; 智力发育评估,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_004,儿童性早熟,,endocrine_disorder,pediatric_endocrine_disease,clinical_manifestations.growth_patterns.advanced_bone_age,骨龄超前,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_004,儿童性早熟,,endocrine_disorder,pediatric_endocrine_disease,clinical_manifestations.growth_patterns.early_epiphyseal_fusion,骨骺过早闭合,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_004,儿童性早熟,,endocrine_disorder,pediatric_endocrine_disease,diagnostic_evaluation.imaging_studies.bone_age.finding,骨龄超前>2年,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_004,儿童性早熟,,endocrine_disorder,pediatric_endocrine_disease,treatment.central_precocious_puberty.monitoring.side_effects,骨密度、情绪变化,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_004,儿童性早熟,,endocrine_disorder,pediatric_endocrine_disease,monitoring_and_follow_up.treatment_response,第二性征进展; 生长速度; 骨龄进展; 激素水平,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_004,儿童性早熟,,endocrine_disorder,pediatric_endocrine_disease,monitoring_and_follow_up.side_effects_monitoring,骨密度(DXA); 情绪行为变化; 注射部位反应; 体重变化,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_004,儿童性早熟,,endocrine_disorder,pediatric_endocrine_disease,monitoring_and_follow_up.long_term_outcomes,最终身高; 生育能力; 心理社会适应; 骨健康,Endocrine Society Clinical Practice Guidelines,pediatric_endocrine_entities.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.bone_metabolism.osteoporosis.relationship_type,继发性关联,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hashimoto_thyroiditis_relationships.target_diseases.bone_metabolism.osteoporosis.mechanism,长期甲状腺激素替代治疗影响骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,addison_disease_relationships.target_diseases.gonadal_dysfunction.primary_hypogonadism.impact,加重骨质疏松和代谢异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.bone_endocrine.osteoporosis.relationship_type,多因素,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.bone_endocrine.osteoporosis.mechanisms,疾病本身的炎症; 糖皮质激素治疗; 维生素D缺乏; 性激素缺乏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.bone_metabolism.osteoporosis.relationship_type,多重机制,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.bone_metabolism.osteoporosis.prevalence,30-50%的RA患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,rheumatoid_arthritis_relationships.target_diseases.bone_metabolism.osteoporosis.mechanisms,炎性细胞因子影响骨重建; 糖皮质激素治疗; 活动受限; 维生素D缺乏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.bone_health.osteoporosis.relationship_type,多因素,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,sjogren_syndrome_relationships.target_diseases.bone_health.osteoporosis.mechanisms,慢性炎症; 维生素D吸收不良; 激素缺乏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.description,骨代谢疾病与内分泌系统的复杂相互作用关系,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.prevalence,1型糖尿病患者骨密度降低风险增加2-4倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.mechanisms,胰岛素缺乏影响成骨细胞功能; IGF-1水平下降影响骨形成; 高血糖产生糖基化终产物损伤骨基质; 慢性炎症状态影响骨重建,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.clinical_implications,年轻患者也需要骨密度筛查; 血糖控制对骨健康至关重要; 骨折愈合可能延迟,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.bone_disease_patterns.osteoporosis,主要表现为骨质疏松,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_1_diabetes.bone_disease_patterns.fracture_sites,椎体、髋部骨折风险增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.paradox,骨密度可正常或增加但骨折风险仍增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.mechanisms,骨质量下降（微结构损伤）; 糖基化终产物影响胶原交联; 跌倒风险增加; 某些降糖药物影响骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.drug_considerations.thiazolidinediones,噻唑烷二酮类增加骨折风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.drug_considerations.sglt2_inhibitors,SGLT2抑制剂可能影响骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.diabetes_mellitus.type_2_diabetes.drug_considerations.insulin,胰岛素有益于骨健康,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hyperthyroidism.prevalence,甲亢患者骨质疏松发病率增加5-10倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hyperthyroidism.mechanisms,甲状腺激素直接刺激破骨细胞活性; 骨转换加速，吸收>形成; 钙磷代谢紊乱; 维生素D代谢异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hyperthyroidism.reversibility,甲亢控制后骨密度可部分恢复,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hyperthyroidism.monitoring,需要骨密度定期监测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hypothyroidism.untreated_effects,未治疗甲减相对保护骨密度,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.hypothyroidism.treatment_effects,过度LT4替代可能增加骨丢失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.thyroid_cancer_survivors.tsh_suppression_therapy,TSH抑制治疗增加骨丢失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.thyroid_disorders.thyroid_cancer_survivors.risk_stratification,根据复发风险平衡治疗获益与骨风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.primary_hyperparathyroidism.bone_disease,甲状旁腺性骨病的直接原因,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.primary_hyperparathyroidism.manifestations,骨质疏松（皮质骨>松质骨）; 骨膜下皮质骨吸收; 褐色瘤形成; 病理性骨折,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.primary_hyperparathyroidism.surgical_benefit,甲状旁腺切除术后骨密度显著改善,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.hypoparathyroidism.relationship_type,治疗相关骨病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.hypoparathyroidism.mechanisms,PTH缺乏导致骨转换极度下降; 骨基质矿化异常; 皮质骨增厚但骨质量下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.hypoparathyroidism.treatment_challenges,传统治疗难以维持正常骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.secondary_hyperparathyroidism.ckd_mbd,慢性肾病骨矿物质代谢紊乱,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.parathyroid_disorders.secondary_hyperparathyroidism.mixed_bone_disease,骨软化症与纤维囊性骨炎并存,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.cushings_syndrome.prevalence,Cushing综合征患者骨质疏松发病率>50%,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.cushings_syndrome.mechanisms,皮质醇抑制成骨细胞分化和功能; 促进破骨细胞活性; 抑制肠道钙吸收; 影响性激素合成,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.cushings_syndrome.rapid_onset,骨丢失可在短期内快速发生,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.cushings_syndrome.fracture_risk,椎体骨折风险极高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.addison_disease.cortisol_deficiency,皮质醇缺乏对骨代谢的影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.addison_disease.treatment_effects,糖皮质激素替代治疗的骨影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.adrenal_disorders.addison_disease.monitoring,需要平衡激素替代与骨健康,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.menopause.estrogen_deficiency,雌激素缺乏是绝经后骨质疏松主因,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.menopause.bone_loss_pattern,绝经后5-10年骨丢失加速,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.male_hypogonadism.testosterone_effects,睾酮对男性骨健康的重要性,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.male_hypogonadism.replacement_therapy,睾酮替代治疗改善骨密度,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.pcos.androgen_effects,雄激素过多对骨代谢的影响,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.reproductive_endocrine.pcos.insulin_resistance,胰岛素抵抗与骨代谢相互作用,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.acromegaly.active_disease,活动期骨转换增加但骨密度可能正常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.acromegaly.post_treatment,治疗后骨密度可能下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.acromegaly.fracture_paradox,骨密度正常但骨折风险可能增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.gh_deficiency.adult_ghd,成人生长激素缺乏导致骨密度下降,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.growth_hormone_disorders.gh_deficiency.replacement_therapy,GH替代治疗改善骨代谢,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.target_diseases.vitamin_d_disorders.vitamin_d_deficiency.primary_cause,骨软化症的主要病因,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.multidisciplinary_care.orthopedist,骨科并发症处理,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.multidisciplinary_care.rheumatologist,骨代谢专业评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.treatment_priorities.bone_specific_therapy,必要时加用骨特异性治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,bone_metabolism_endocrine_relationships.integrated_management_approaches.treatment_priorities.fracture_prevention,骨折预防为核心目标,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.vitamin_d_endocrine_network.parathyroid_interactions.secondary_hyperparathyroidism.mechanism,维生素D缺乏→PTH升高→骨代谢异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,nutritional_metabolic_endocrine_relationships,nutritional metabolic endocrine relationships,,,,target_diseases.vitamin_d_endocrine_network.parathyroid_interactions.secondary_hyperparathyroidism.clinical_cascade,骨质疏松、肾结石、心律不齐风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.male_hypogonadism_associations.growth_hormone_interactions.bone_health,协同维护骨密度,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.bone_metabolism_effects.estrogen_deficiency,雌激素缺乏导致快速骨丢失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.poi_endocrine_network.bone_metabolism_effects.fracture_risk,骨折风险增加3-7倍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.lactation_hormonal_effects.bone_calcium_mobilization,哺乳期骨钙动员,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.poi_hrt_strategies.bone_health_focus,骨密度监测和干预,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024,rheumatic_endocrine_relationships.csv
